Citation Impact
Citing Papers
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
A2A adenosine receptor protects tumors from antitumor T cells
2006
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
1999
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
1997 Nature
Requirement of Cysteine-rich Repeats of the Fas Receptor for Binding by the Fas Ligand
1997
Matters of life and death: programmed cell death at Cold Spring Harbor
1998
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
2006
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
1999 Standout
Oncogenic kinase signalling
2001 StandoutNature
Apoptosis by Death Factor
1997 Standout
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
1998 StandoutNatureNobel
The Human T Cell Response to Melanoma Antigens
2006
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Human tumor antigens recognized by T-cells
1997
Tolerance and Autoimmunity
2001
The Hallmarks of Cancer
2000 Standout
Low‐avidity recognition by CD4 + T cells directed to self‐antigens
2003
TGFβ: the molecular Jekyll and Hyde of cancer
2006
Antibody targeted drugs as cancer therapeutics
2006
The biochemistry of apoptosis
2000 StandoutNature
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
2002
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
1997
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
1998
The C. elegans Protein EGL-1 Is Required for Programmed Cell Death and Interacts with the Bcl-2–like Protein CED-9
1998 StandoutNobel
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
2011
TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis
1997
Immunity, Inflammation, and Cancer
2010 Standout
The biology of the combretastatins as tumour vascular targeting agents
2002
TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)
1997
Cytokines in cancer pathogenesis and cancer therapy
2004
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection
2004
Mammalian MAP kinase signalling cascades
2001 StandoutNature
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
1998 StandoutNature
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Clonal evolution in cancer
2012 StandoutNature
Tumour necrosis factor and cancer
2009
Errors of homeostasis and deregulated apoptosis
1997
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
1997
The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy
1997
Cancer-related inflammation
2008 StandoutNature
Inhibition of death receptor signals by cellular FLIP
1997 StandoutNature
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice
2002 StandoutNobel
Dysregulation of Apoptosis in Cancer
1999
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
The Central Role of CD4+ T Cells in the Antitumor Immune Response
1998
The Bcl-2 Protein Family: Arbiters of Cell Survival
1998 StandoutScience
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
1998
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
2001
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
1999
High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals
1999
Functional Analysis of Antigen-Specific T Lymphocytes by Serial Measurement of Gene Expression in Peripheral Blood Mononuclear Cells and Tumor Specimens
1999
Tumor immune escape mechanisms: impact of the neuroendocrine system
2006
Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)
1998 Science
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
2002
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Cutting Edge: Lymphocyte Inhibitor of TRAIL (TNF-Related Apoptosis-Inducing Ligand): A New Receptor Protecting Lymphocytes from the Death Ligand TRAIL
1998
Analysis of the B‐cell repertoire against antigens expressed by human neoplasms
2002
Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity
1998
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
2004
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors
2001
Death Receptors: Signaling and Modulation
1998 StandoutScience
A Self-Assembled Multivalent Pseudopolyrotaxane for Binding Galectin-1
2004 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Requirement for the CD95 Receptor-Ligand Pathway in c-Myc-Induced Apoptosis
1997 Science
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
2002 StandoutNobel
Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations
2000 StandoutScienceNobel
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Does the Immune System See Tumors as Foreign or Self?
2003
Immunosuppressive Strategies that are Mediated by Tumor Cells
2006
Surfing the p53 network
2000 StandoutNature
FLIP Prevents Apoptosis Induced by Death Receptors But Not by Perforin/Granzyme B, Chemotherapeutic Drugs, and Gamma Irradiation
1998
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
2011
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL.
1998
Identification of Amino Acid Residues Important for Ligand Binding to Fas
1997
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
1998
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
Caspases: Enemies Within
1998 StandoutScience
Withdrawal of Survival Factors Results in Activation of the JNK Pathway in Neuronal Cells Leading to Fas Ligand Induction and Cell Death
1999
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Works of D Liénard being referenced
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
1992
Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
2001
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
1996 Science
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
1997
Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
1999